Day One Biopharmaceuticals (DAWN) Short Interest Ratio & Short Volume → CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad) Free DAWN Stock Alerts $16.17 +0.14 (+0.87%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Day One Biopharmaceuticals Short Interest DataCurrent Short Volume11,190,000 sharesPrevious Short Volume8,940,000 sharesChange Vs. Previous Month+25.17%Dollar Volume Sold Short$191.35 millionShort Interest Ratio / Days to Cover10.7Last Record DateApril 30, 2024Outstanding Shares87,390,000 sharesFloat Size60,600,000 sharesShort Percent of Float18.47%Today's Trading Volume421,575 sharesAverage Trading Volume861,762 sharesToday's Volume Vs. Average49% Short Selling Day One Biopharmaceuticals ? Sign up to receive the latest short interest report for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatDAWN Short Interest Over TimeDAWN Days to Cover Over TimeDAWN Percentage of Float Shorted Over Time Ad Stansberry ResearchA letter is coming from the "Bureau of the Fiscal Service".Is your bank next? A powerful new trend is spreading like wildfire inside the US financial system. At least 41 banks are already involved. But the Federal Reserve predicts that number will grow fast.See if your bank is involved right here. Day One Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202411,190,000 shares $191.35 million +25.2%18.5%10.7 $17.10 4/15/20248,940,000 shares $123.82 million -0.5%15.2%10.6 $13.85 3/31/20248,980,000 shares $148.35 million -6.6%15.2%14.5 $16.52 3/15/20249,610,000 shares $138.29 million -0.9%16.3%16.6 $14.39 2/29/20249,700,000 shares $162.28 million -0.2%16.5%17.3 $16.73 2/15/20249,720,000 shares $149.30 million +6.2%16.6%19.5 $15.36 Get the Latest News and Ratings for DAWN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/20249,150,000 shares $137.71 million -15.3%15.5%17.4 $15.05 1/15/202410,800,000 shares $150.55 million +0.5%19.1%16.7 $13.94 12/31/202310,750,000 shares $156.95 million -2.3%19.0%15.1 $14.60 12/15/202311,000,000 shares $156.86 million +2.3%19.4%14.8 $14.26 11/30/202310,750,000 shares $124.49 million -0.7%19.0%13 $11.58 11/15/202310,830,000 shares $130.72 million -8.5%19.2%13.1 $12.07 10/31/202311,840,000 shares $140.07 million +4.3%21.0%14.1 $11.83 10/15/202311,350,000 shares $125.64 million -7.8%20.1%14.7 $11.07 9/30/202312,310,000 shares $151.04 million -0.5%21.3%16.7 $12.27 9/15/202312,370,000 shares $172.19 million +2.7%21.4%16 $13.92 8/31/202312,050,000 shares $162.55 million -0.2%20.4%13.2 $13.49 8/15/202312,070,000 shares $166.32 million -12.4%20.4%10.3 $13.78 7/31/202313,780,000 shares $182.45 million +1.0%30.1%11.5 $13.24 7/15/202313,640,000 shares $158.91 million -2.4%29.8%10.7 $11.65 6/30/202313,980,000 shares $166.92 million +3.5%30.6%11 $11.94 6/15/202313,510,000 shares $177.52 million +35.1%29.6%10.1 $13.14 5/31/202310,000,000 shares $133 million +7.2%21.5%8.8 $13.30 5/15/20239,330,000 shares $129.50 million +2.3%20.1%11.3 $13.88 4/30/20239,120,000 shares $113.09 million +16.0%20.0%11.7 $12.40 4/15/20237,860,000 shares $96.99 million +6.1%17.3%11.6 $12.34 3/31/20237,410,000 shares $99.07 million +11.3%16.3%10.7 $13.37 3/15/20236,660,000 shares $124.34 million +12.1%14.6%12.1 $18.67 2/28/20235,940,000 shares $109.41 million +4.4%13.0%10.7 $18.42 2/15/20235,690,000 shares $111.18 million +6.6%12.5%10.7 $19.54 1/31/20235,340,000 shares $116.25 million -4.5%11.6%10.1 $21.77 1/15/20235,590,000 shares $127.62 million +25.1%14.0%10.5 $22.83 12/30/20224,470,000 shares $96.19 million +3.5%11.2%8.4 $21.52 12/15/20224,320,000 shares $92.53 million -1.1%11.0%8.6 $21.42 11/30/20224,370,000 shares $92.78 million -4.2%11.1%7.3 $21.23 11/15/20224,560,000 shares $99.82 million -9.5%11.6%7.5 $21.89 10/31/20225,040,000 shares $106.55 million -7.9%12.7%7.7 $21.14 10/15/20225,470,000 shares $114.21 million -8.5%14.6%8.5 $20.88 9/30/20225,980,000 shares $119.78 million -3.1%17.0%9.5 $20.03 9/15/20226,170,000 shares $140.55 million -9.3%17.5%9 $22.78I’m afraid WWIII is a very real possibility (Ad)As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film.Take a look. DAWN Short Interest - Frequently Asked Questions What is Day One Biopharmaceuticals' current short interest? Short interest is the volume of Day One Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 11,190,000 shares of DAWN short. 18.47% of Day One Biopharmaceuticals' shares are currently sold short. Learn More on Day One Biopharmaceuticals' current short interest. What is a good short interest ratio for Day One Biopharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DAWN shares currently have a short interest ratio of 11.0. Learn More on Day One Biopharmaceuticals's short interest ratio. Which institutional investors are shorting Day One Biopharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Day One Biopharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Day One Biopharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 18.47% of Day One Biopharmaceuticals' floating shares are currently sold short. Is Day One Biopharmaceuticals' short interest increasing or decreasing? Day One Biopharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totaling 11,190,000 shares, an increase of 25.2% from the previous total of 8,940,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Day One Biopharmaceuticals' float size? Day One Biopharmaceuticals currently has issued a total of 87,390,000 shares. Some of Day One Biopharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Day One Biopharmaceuticals currently has a public float of 60,600,000 shares. How does Day One Biopharmaceuticals' short interest compare to its competitors? 18.47% of Day One Biopharmaceuticals' shares are currently sold short. Here is how the short interest of companies compare to Day One Biopharmaceuticals: Avadel Pharmaceuticals plc (5.30%), Dynavax Technologies Co. (14.99%), Pacira BioSciences, Inc. (7.73%), Morphic Holding, Inc. (12.82%), Akero Therapeutics, Inc. (12.44%), ANI Pharmaceuticals, Inc. (1.09%), Kiniksa Pharmaceuticals, Ltd. (5.51%), Ligand Pharmaceuticals Incorporated (4.42%), Gyre Therapeutics, Inc. (0.54%), Arcus Biosciences, Inc. (16.36%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Day One Biopharmaceuticals stock? Short selling DAWN is an investing strategy that aims to generate trading profit from Day One Biopharmaceuticals as its price is falling. DAWN shares are trading up $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Day One Biopharmaceuticals? A short squeeze for Day One Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of DAWN, which in turn drives the price of the stock up even further. How often is Day One Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DAWN, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: AVDL Short Interest DVAX Short Interest PCRX Short Interest MORF Short Interest AKRO Short Interest ANIP Short Interest KNSA Short Interest LGND Short Interest GYRE Short Interest RCUS Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DAWN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceA once-in-a-century investment opportunityStansberry Research[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits